AssuredPartners Investment Advisors’s AstraZeneca AZN Stock Holding History

AssuredPartners Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$208K	Buy	+1,026	New	+$198K	0.02%	379

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

AssuredPartners Investment Advisors's AZN Position: Q1 2026 in Review

AssuredPartners Investment Advisors opened a new position in AstraZeneca (AZN) in Q1 2026: 1,026 shares worth $208K. The stake represents 0.02% of the portfolio and ranks #379 among its holdings.

1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

AssuredPartners Investment Advisors held 1,026 shares of AstraZeneca worth $208K as of Q1 2026.
AstraZeneca was a new AssuredPartners Investment Advisors position in Q1 2026.
AstraZeneca made up 0.02% of AssuredPartners Investment Advisors's portfolio in Q1 2026, its #379 holding.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.